COVID-19 detection in NAAT-negative patients, especially individuals who present 9 to 14 days post symptom onset Epidemiological studies of disease (tracking the spread of virus) Identification of convalescent plasma donors Potentially verification of vaccine response once antibody correlates of protectio...
After testing in mice, the formula went into US testing in ferrets, one of the animal species that like humans is susceptible to SARS-CoV-2 virus infection. The results were promising, indicating that two doses of the vaccine was able to prevent COVID-19 lung investion and also prevent sh...
Vaccines to prevent a COVID-19 (SARS-CoV-2) infection are now available for anyone over 5 years of age. The two first cleared for emergency use in the U.S. by the FDA were the Pfizer/BioNTech vaccine and the Moderna vaccine. Also, the Johnson & Johnson vaccine was also cleared shortl...
Vaccines to prevent a COVID-19 (SARS-CoV-2) infection are now available for anyone over 5 years of age. The two first cleared for emergency use in the U.S. by the FDA were the Pfizer/BioNTech vaccine and the Moderna vaccine. Also, the Johnson & Johnson vaccine was also cleared shortl...
Yesterday, NIH and Moderna announced the start of a multi-site, Phase 3 clinical trial of a candidate vaccine for COVID-19. This candidate vaccine uses messenger RNA, or mRNA, a “codebook” that cellular machinery “reads” in order to build proteins. F
The results are in line with other studies recently published. Researchers at the University of Oxford said on Monday that they found the two-dose Pfizer and AstraZeneca COVID-19 vaccine regimens do not induce enough neutralizing antibodies against the new variant. ...
A COVID-19 vaccine candidate developed by the University of Saskatchewan's (USask) Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac) has cleared another major milestone in moving towards human clinical trials: the n
Absalon, et al. Safety and Efficacy of the GNT162b2 mRNA Covid-19 vaccine NEJM (2020), 10.1056/NEJMoa2034577 Google Scholar Cited by (14) Animal models for COVID-19: advances, gaps and perspectives 2022, Signal Transduction and Targeted Therapy Cell and Animal Models for SARS-CoV-2 ...
19 vaccine to make it easier to get COVID. Jiang explains, “Decades ago, vaccines developed against another coronavirus, feline infectious peritonitis virus, increased cats’ risk of developing the disease caused by the virus. Similar phenomena have been seen in animal studies for other viruses,...
These results constitute a warning that COVID-19 vaccine candidates should be comprehensively assessed in diverse animal models (that is, young and old animals, and male and female animals) to confirm their safety and efficacy and that human study participants should reflect diverse populations. ...